Actionable news
0
All posts from Actionable news
Actionable news in DVAX: Dynavax Technologies Corporation,

The FDA Just Blocked Approval On Dynavax's Hep-B Drug For The Second Time

Dynavax Technologies Corporation NASDAQ:DVAX - The FDA Just Blocked Approval On Dynavax's Hep-B Drug For The Second Time

Shares of Dynavax Technologies Corporation DVAX 27.98% are selling off Friday afternoon after the FDA cancelled their upcoming ADCOM meeting for their Heplisav drug. ADCOM meetings advise on whether or not to approve a drug.

The meeting was cancelled to allow time to review several outsanding issues with the drug.

This was Dynavax's second attempt at approval for Heplisav, a Hepatitis B vaccine. They were originally rejected in November of 2012.

At time of writing, shares were down 33% to $10.60.

Benzinga Pro subscribers were alerted to the news first.

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.